SLC47A1

Multidrug and toxin extrusion protein 1 · Q96FL8 · SLC47A1 on Sugi Atlas →

33,850 patent compounds predicted against SLC47A1, 26,695 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Famotidine (SCHEMBL973)	1.00	2/20
Rimantadine (SCHEMBL2981)	1.00	2/20
Rimantadine (SCHEMBL2982)	1.00	2/20
Amantadine (SCHEMBL4098)	1.00	2/20
Famotidine (SCHEMBL39237)	1.00	2/20
Cimetidine (SCHEMBL226031)	1.00	2/20
Famotidine (SCHEMBL458654)	1.00	2/20
Cimetidine (SCHEMBL534523)	1.00	2/20
Rimantadine (SCHEMBL40906)	0.95	2/20
Amantadine (SCHEMBL40713)	0.93	2/20
Amantadine (SCHEMBL572799)	0.93	2/20
Amantadine (SCHEMBL669105)	0.93	2/20
Irinotecan (SCHEMBL478241)	0.84	2/20
Cimetidine (SCHEMBL1093)	0.69	2/20
Cimetidine (SCHEMBL42142)	0.67	2/20
Famotidine (SCHEMBL188452)	0.67	2/20
Cimetidine (SCHEMBL42143)	0.66	2/20
Cimetidine (SCHEMBL534521)	0.65	2/20
Cimetidine (SCHEMBL534522)	0.65	2/20
SCHEMBL138375	0.62	2/20

Clinical trials — most relevant to SLC47A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery	PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies	PHASE1	COMPLETED
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects	PHASE1	ACTIVE_NOT_RECRUITING
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects	PHASE1	UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Pharmacogenetics in Non Small Cell Lung Cancer	nan	UNKNOWN
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District	nan	UNKNOWN
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC47A1 binder may also engage these)

Protein	Name	Similarity
Q5RFD2	—	1.000	Q5RFD2 →
Q8K0H1	—	1.000	Q8K0H1 →
Q5I0E9	—	0.997	Q5I0E9 →
A7KAU2	—	0.997	A7KAU2 →
SLC47A2	Multidrug and toxin extrusion protein 2	0.993	landscape →
Q3V050	—	0.987	Q3V050 →
Q5R7E4	—	0.985	Q5R7E4 →
A4IIS8	—	0.984	A4IIS8 →
A7KAU3	—	0.984	A7KAU3 →
A1L1P9	—	0.982	A1L1P9 →
O49660	—	0.978	O49660 →
F4J158	—	0.969	F4J158 →
Q8L616	—	0.969	Q8L616 →
Q9USK3	—	0.965	Q9USK3 →
F4JH46	—	0.965	F4JH46 →
F4I4Q3	—	0.963	F4I4Q3 →
Q8WUX1	—	0.963	Q8WUX1 →
F4HPH1	—	0.962	F4HPH1 →
SLC5A11	Sodium/myo-inositol cotransporter 2	0.960	landscape →
B2RX12	—	0.960	B2RX12 →
F4HPH2	—	0.960	F4HPH2 →
P70423	—	0.960	P70423 →
Q9LPV4	—	0.960	Q9LPV4 →
F4JTB3	—	0.960	F4JTB3 →
Q9SVG0	—	0.959	Q9SVG0 →
Q8RXK1	—	0.959	Q8RXK1 →
A8I499	—	0.959	A8I499 →
Q6DCE8	—	0.959	Q6DCE8 →
Q4LE88	—	0.959	Q4LE88 →
P70187	—	0.959	P70187 →